premature ejaculation
Conditions
Interventions
Premature ejaculation group/Normal group:none
Sponsors
The Second Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine
Eligibility
Sex/Gender
Male
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-50, male; 2. in general good health, with a stable heterosexual sexual partner for more than 3 months; 3. definite premature ejaculation (PEDT score =11); 4. a medical history of at least 3 months and less than 10 years; 5. normal erections (International Index of Erectile Function (IIEF) score > 21) in all patients; 6. normal serum total testosterone, prolactin and thyrotropin levels; 7. all participants were non-circumcised or previously circumcised; 8. no PE treatment medications were used within 2 weeks prior to grouping; if there was a history of medication within 2 weeks, a 14-day washout period needed to be met before enrollment; 9. patients voluntarily agreed to participate in this study and signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. severe prostatitis symptoms, lower urinary tract symptoms, urinary tract infections, and other conditions, history of psychotropic substance abuse; 2. history of severe mental illness, such as mood and anxiety disorders, schizophrenia; and 3. history of medications that affect ejaculation in the past 6 months 4. severe erectile dysfunction with an International Index of Erectile Function (IIEF) score =21 5. Hypertension with poor blood pressure control (systolic blood pressure = 160 mmHg and diastolic blood pressure = 100 mmHg after treatment); 6. poor glycemic control in diabetes mellitus with fasting plasma glucose (FPG) level > 7.0 mmol/l (126 mg/dl); 7. oral antibiotics within the previous 2 weeks or personal history of inflammatory bowel disease (IBD), irritable bowel syndrome, autoimmune disease, liver disease, diarrhea and malignancy; 8. Individuals who have participated in any other medical device or drug clinical study within the past 3 months; or other patients who are considered by the investigator to be unsuitable for participation in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Distribution of intestinal flora; | — |
Secondary
| Measure | Time frame |
|---|---|
| neurotransmitter;mediator of inflammation; | — |
Countries
China
Contacts
Public ContactYue Duan
The Second Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine
Outcome results
None listed